Individualising Netilmicin Dosing in Neonates

Catherine M.T. Sherwin; Roland S. Broadbent; Natalie J. Medlicott; David M. Reith

doi:10.1007/s00228-008-0536-0

Individualising Netilmicin Dosing in Neonates

Catherine M.T. Sherwin, Roland S. Broadbent, Natalie J. Medlicott, David M. Reith

Research output: Contribution to journal › Article › peer-review

Abstract

<p> <dl id="x-x-x-citationFields"> <dd> PURPOSE: The aim of this study was develop an optimal dosingregimen for netilmicin in neonates. METHODS: This was a population pharmacokinetic study in 97 neonates aged from 2 to 28 days after the due date who were being treated with netilmicin for suspected sepsis. The model was used to simulate dosing regimens. RESULTS: The principle factors influencing netilmicin clearance (CL) were postmenstrual age (PMA) and current body weight (CWT), and the principal determinant of volume of distribution (V) was CWT. The final covariate model was CL = 0.192 x (CWT/2)(1.35) x (PMA/40)(1.03), V = 1.5 x (CWT/2)(0.3). The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates < or =27, 28-30, 31-33 and > or =34 weeks PMA, respectively. CONCLUSION: Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT. </dd> </dl></p>

Original language	English
Pages (from-to)	1201-1208
Number of pages	8
Journal	European Journal of Clinical Pharmacology
Volume	64
Issue number	12
DOIs	https://doi.org/10.1007/s00228-008-0536-0
State	Published - Dec 2008
Externally published	Yes

ASJC Scopus Subject Areas

Pharmacology
Pharmacology (medical)

Keywords

Individualised dosing
Neonates
Netilmicin
Population pharmacokinetics
Research Support, Non-U.S. Gov't
Anti-Bacterial Agents / administration & dosage*
Anti-Bacterial Agents / pharmacokinetics
Anti-Bacterial Agents / therapeutic use
Apgar Score
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gestational Age
Humans
Infant, Newborn
Infusions, Intravenous
Male
Medical Records
Metabolic Clearance Rate
Models, Biological
Netilmicin / administration & dosage*
Netilmicin / pharmacokinetics
Netilmicin / therapeutic use
Predictive Value of Tests
Retrospective Studies
Sepsis / drug therapy*
Sepsis / metabolism
Anti-Bacterial Agents

Disciplines

Pediatrics

Access to Document

10.1007/s00228-008-0536-0

Cite this

@article{4009701da6a24ef6a825595736eed7b6,

title = "Individualising Netilmicin Dosing in Neonates",

abstract = " PURPOSE: The aim of this study was develop an optimal dosingregimen for netilmicin in neonates. METHODS: This was a population pharmacokinetic study in 97 neonates aged from 2 to 28 days after the due date who were being treated with netilmicin for suspected sepsis. The model was used to simulate dosing regimens. RESULTS: The principle factors influencing netilmicin clearance (CL) were postmenstrual age (PMA) and current body weight (CWT), and the principal determinant of volume of distribution (V) was CWT. The final covariate model was CL = 0.192 x (CWT/2)(1.35) x (PMA/40)(1.03), V = 1.5 x (CWT/2)(0.3). The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates < or =27, 28-30, 31-33 and > or =34 weeks PMA, respectively. CONCLUSION: Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT. ",

keywords = "Individualised dosing, Neonates, Netilmicin, Population pharmacokinetics, Research Support, Non-U.S. Gov't, Anti-Bacterial Agents / administration & dosage*, Anti-Bacterial Agents / pharmacokinetics, Anti-Bacterial Agents / therapeutic use, Apgar Score, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Gestational Age, Humans, Infant, Newborn, Infusions, Intravenous, Male, Medical Records, Metabolic Clearance Rate, Models, Biological, Netilmicin / administration & dosage*, Netilmicin / pharmacokinetics, Netilmicin / therapeutic use, Predictive Value of Tests, Retrospective Studies, Sepsis / drug therapy*, Sepsis / metabolism, Anti-Bacterial Agents",

author = "Sherwin, {Catherine M.T.} and Broadbent, {Roland S.} and Medlicott, {Natalie J.} and Reith, {David M.}",

year = "2008",

month = dec,

doi = "10.1007/s00228-008-0536-0",

language = "English",

volume = "64",

pages = "1201--1208",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

number = "12",

}

TY - JOUR

T1 - Individualising Netilmicin Dosing in Neonates

AU - Sherwin, Catherine M.T.

AU - Broadbent, Roland S.

AU - Medlicott, Natalie J.

AU - Reith, David M.

PY - 2008/12

Y1 - 2008/12

N2 - PURPOSE: The aim of this study was develop an optimal dosingregimen for netilmicin in neonates. METHODS: This was a population pharmacokinetic study in 97 neonates aged from 2 to 28 days after the due date who were being treated with netilmicin for suspected sepsis. The model was used to simulate dosing regimens. RESULTS: The principle factors influencing netilmicin clearance (CL) were postmenstrual age (PMA) and current body weight (CWT), and the principal determinant of volume of distribution (V) was CWT. The final covariate model was CL = 0.192 x (CWT/2)(1.35) x (PMA/40)(1.03), V = 1.5 x (CWT/2)(0.3). The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates < or =27, 28-30, 31-33 and > or =34 weeks PMA, respectively. CONCLUSION: Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT.

AB - PURPOSE: The aim of this study was develop an optimal dosingregimen for netilmicin in neonates. METHODS: This was a population pharmacokinetic study in 97 neonates aged from 2 to 28 days after the due date who were being treated with netilmicin for suspected sepsis. The model was used to simulate dosing regimens. RESULTS: The principle factors influencing netilmicin clearance (CL) were postmenstrual age (PMA) and current body weight (CWT), and the principal determinant of volume of distribution (V) was CWT. The final covariate model was CL = 0.192 x (CWT/2)(1.35) x (PMA/40)(1.03), V = 1.5 x (CWT/2)(0.3). The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates < or =27, 28-30, 31-33 and > or =34 weeks PMA, respectively. CONCLUSION: Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT.

KW - Individualised dosing

KW - Neonates

KW - Netilmicin

KW - Population pharmacokinetics

KW - Research Support, Non-U.S. Gov't

KW - Anti-Bacterial Agents / administration & dosage

KW - Anti-Bacterial Agents / pharmacokinetics

KW - Anti-Bacterial Agents / therapeutic use

KW - Apgar Score

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Female

KW - Gestational Age

KW - Humans

KW - Infant, Newborn

KW - Infusions, Intravenous

KW - Male

KW - Medical Records

KW - Metabolic Clearance Rate

KW - Models, Biological

KW - Netilmicin / administration & dosage

KW - Netilmicin / pharmacokinetics

KW - Netilmicin / therapeutic use

KW - Predictive Value of Tests

KW - Retrospective Studies

KW - Sepsis / drug therapy

KW - Sepsis / metabolism

KW - Anti-Bacterial Agents

UR - http://www.scopus.com/inward/record.url?scp=57049183107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049183107&partnerID=8YFLogxK

UR - https://corescholar.libraries.wright.edu/pediatrics/213

U2 - 10.1007/s00228-008-0536-0

DO - 10.1007/s00228-008-0536-0

M3 - Article

C2 - 18685839

SN - 0031-6970

VL - 64

SP - 1201

EP - 1208

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

IS - 12

ER -

Individualising Netilmicin Dosing in Neonates

Abstract

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

Other files and links

Cite this